Congresos

Adverse events of interest with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive chronic lymphocytic leukemia A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) A qualitative study to explore the patient experience of continuous covalent bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL): study methodology AdvanTIG-101: a Phase 1b/2 study of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) or rituximab in relapsed/refractory diffuse large b-cell lymphoma BGB-11417-302, a Phase 3, randomized, double-blind study of sonrotoclax (BGB-11417) + zanubrutinib vs placebo + zanubrutinib in patients with relapsed or refractory mantle cell lymphoma Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL: results in SEQUOIA arm D Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma Comparative Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC) Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive chronic lymphocytic leukemia: a matching-adjusted indirect comparison Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia Final analysis of a Phase 1 study of zanubrutinib (Zanu) plus lenalidomide (Len) in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL) Final independent review data supports sustained benefit of zanubrutinib over ibrutinib in patients with R/R CLL/SLL in ALPINE Preferences for treatment in first-line chronic lymphocytic leukemia: a multi-criteria decision analysis in Italy Primary analysis results of novel bcl2 inhibitor sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory b-cell malignancies Real-World Zanubrutinib Treatment Paterns in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Among US Community Oncology Patients With Prior Acalabrutinib Therapy Real-World bruton tyrosine kinase inhibitor use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma Real-World comparative effectiveness of first-line bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia Real-World treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: age-related disparity Real-World zanubrutinib treatment paterns in mantle cell lymphoma among US community oncology patients with prior bruton tyrosine kinase inhibitor therapy Real-world burden of disease, treatment paterns and outcomes in pa􀆟ents with mantle cell lymphoma (MCL) Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent bruton tyrosine kinase inhibitors (cBTKi): A Real-World study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: a real-world study Sonrotoclax monotherapy for treatment of patients with relapsed/refractory CLL: data from an ongoing Phase 1/1B study (BGB-11417-101) Updated efficacy & safety of the bruton tyrosine kinase (btk) degrader BGB-16673 in patients with relapsed/refractory waldenström macroglobulinemia (WM): ongoing phase (PH) 1 CADANCE-101 study results Updated efficacy and safety of the bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (PTS) with relapsed or refractory (R/R) CLL/SLL: results from the ongoing Phase (PH) 1 CADANCE-101 study Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma: an all-oral treatment Updated results from the Phase 1 study of sonrotoclax (bgb-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responses Updated safety & antileukemic activity data of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia unfit for intensive chemotherapy Updated safety and antileukemic activity data for sonrotoclax (BGB-11417), a potent and selective bcl2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Updated safety and efficacy results of a Phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory waldenström macroglobulinemia

Examining the impact of tislelizumab added to chemotherapy on health‑related quality of life (HRQoL) outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts survival and disease progression in patients with resectable non-small cell lung cancer (NSCLC): Post-hoc analysis of RATIONALE-315 Systematic literature review (SLR) of disease burden related to first-line (1L) unresectable, locally advanced, or metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma

BGB-16673, a BTK degrader, in patients with R/R CLL/SLL: Preliminary phase 1 results from CaDAnCe-101

Extended follow-up of zanubrutinib-treated patients with Waldenström macroglobulinemia from the ASPEN trial through LTE1 Proposed standard of care for active monitoring in Waldenström macroglobulinemia from a UK-wide patient-expert collaboration Sonrotoclax + zanubrutinib for TN-CLL demonstrates MRD clearance and tolerability in ongoing phase 1/1b (BGB-11417-101)

BGB-16673, a BTK degrader, in patients with R/R CLL/SLL: Preliminary phase 1 results from CaDAnCe-101 Extended follow-up of zanubrutinib-treated patients with Waldenström macroglobulinemia from the ASPEN trial through LTE1 Proposed standard of care for active monitoring in Waldenström macroglobulinemia from a UK-wide patient-expert collaboration Sonrotoclax + zanubrutinib for TN-CLL demonstrates MRD clearance and tolerability in ongoing phase 1/1b (BGB-11417-101)

Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer

Anti-CCR8 mediates long-lasting antitumor immunological memory and enhances anti-tumor immunity in immune-cold cancer through the combination with chemotherapy BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models BGB-A3055, an afucosylated anti-CCR8 antibody, preferentially depletes intratumoral regulatory T cells and inhibits tumor growth in preclinical models BGB-B2033, a novel 4-1BB/GPC3 bispecific antibody, exhibits potent in vitro and in vivo antitumor activity in preclinical models BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model BTK T474I with enhanced kinase activity confers growth advantage over BTK-L528W with kinase deficiency in B malignant cells Deep plasma proteome profiling to discover drug treatment related novel biomarkers in non-small cell lung cancer EGFR x MET TsAb: differentiated MET biparatopic design with optimal MET inhibitory activity to pursue best-in-class opportunity Integrative spatial and single-cell analysis elucidates tumor microenvironment heterogeneity in NSCLC Preclinical characterization of BGB-B3227, a MUC1 x CD16A bispecific engager, for the treatment of MUC1-expressing solid tumor Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer Single-cell gene expression profiling of the tumor immune microenvironment (TIME) and its association with immunotherapy response in syngeneic mouse models Zanubrutinib (zanu) overcomes BTK-V416L resistance in B cell lymphoma models iPSC-derived γδT with novel combinatorial knockout demonstrated significant anti-tumor activity and extended longevity without cytokine support

A first-in-human phase 1a/b study of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors and MTAP deficiency Anti-CCR8 mediates long-lasting antitumor immunological memory and enhances anti-tumor immunity in immune-cold cancer through the combination with chemotherapy BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models BGB-B2033, a novel 4-1BB/GPC3 bispecific antibody, exhibits potent in vitro and vivo antitumor activity in preclinical model BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model BGBA3055, an afucosylated anti-CCR8 antibody, preferentially depletes intratumoral regulatory T cells and inhibits tumor growth in preclinical models BTK T474I with enhanced kinase activity confers growth advantage over BTK-L528W with kinase deficiency in B malignant cells Deep plasma proteome profiling to discover drug treatment related novel biomarkers in non-small cell lung cancer EGFR x MET tsAb: differentiated MET biparatopic design with optimal MET inhibitory activity to pursue best-in-class opportunity Integrative spatial and single-cell analysis elucidates tumor microenvironment heterogeneity in NSCLC Preclinical characterization of BGB-B3227, a MUC1 x CD16A bispecific engager, for the treatment of MUC1-expressing solid tumors: Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer Single-cell gene expression profiling of the tumor immune microenvironment (TIME) and its association with immunotherapy response in syngeneic mouse models Zanubrutinib (zanu) overcomes BTK V416L resistance in B cell lymphoma models iPSC-derived gdT with novel combinatorial KO demonstrated significant anti-tumor activity and extended longevity without cytokine support

L’association sonrotoclax et zanubrutinib permet des taux élevés de clairance de la maladie résiduelle avec une tolérance satisfaisante en première ligne de leucémie lymphoïde chronique : données de l’étude de phase 1/1b en cours BGB-11417-101 Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

Analyse comparative d’efficacité de zanubrutinib plus obinutuzumab dans le lymphome folliculaire en rechute/réfractaire : Growth Modulation Index (GMI) dans l'étude ROSEWOOD Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study Le zanubrutinib a démontré une tolérance et une efficacité chez les patients intolérants à l’acalabrutinib traités pour des néoplasies lymphoïdes B Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Résultats d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton BGB-16673 chez les patients atteints de leucémie lymphoïde chronique/lymphome lymphocytique en rechute et/ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Résultats préliminaires d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton (BTK) BGB-16673 chez les patients atteints de macroglobulinémie de Waldenström (MW) en rechute ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Utilisation des inhibiteurs de tyrosine kinase de Bruton (iBTK) en vie réelle et résultats cliniques chez les patients atteints d’une leucémie lymphoïde chronique (LLC) ou d’un lymphome lymphocytique (LL) Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Analyse comparative d’efficacité de zanubrutinib plus obinutuzumab dans le lymphome folliculaire en rechute/réfractaire : Growth Modulation Index (GMI) dans l'étude ROSEWOOD Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study Le zanubrutinib a démontré une tolérance et une efficacité chez les patients intolérants à l’acalabrutinib traités pour des néoplasies lymphoïdes B L’association sonrotoclax et zanubrutinib permet des taux élevés de clairance de la maladie résiduelle avec une tolérance satisfaisante en première ligne de leucémie lymphoïde chronique : données de l’étude de phase 1/1b en cours BGB-11417-101 Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with CLL/SLL in US community oncology practices Résultats d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton BGB-16673 chez les patients atteints de leucémie lymphoïde chronique/lymphome lymphocytique en rechute et/ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Résultats préliminaires d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton (BTK) BGB-16673 chez les patients atteints de macroglobulinémie de Waldenström (MW) en rechute ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101 Utilisation des inhibiteurs de tyrosine kinase de Bruton (iBTK) en vie réelle et résultats cliniques chez les patients atteints d’une leucémie lymphoïde chronique (LLC) ou d’un lymphome lymphocytique (LL) Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase 3 RATIONALE-304 trial Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer (supplement)

Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase 3 RATIONALE-304 trial Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer

Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l'adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JOG/CG) avancé ou métastatique sans surexpression HER2 (HER2-négatif): Étude RATIONALE-305 – Actualisation après 36 mois de suivi Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l’adénocarcinome gastrique ou de la jonction gastro-œsophagienne (AG/JGO), avancé ou métastatique, HER2-négatif: analyse des résultats de l’étude RATIONALE-305 selon différents scores d’expression de PD-L1 Étude RATIONALE-306 comparant le Tislélizumab (TIS) + chimiothérapie (CT) versus placebo (PBO) + CT dans le carcinome épidermoïde de l’œsophage (CEO) avancé ou métastatique : analyse des résultats selon différents scores d’expression de PD-L1 Étude internationale de phase 3 évaluant tislélizumab + chimiothérapie (CT) par rapport à un placebo + CT en première ligne de traitement du carcinome épidermoïde de l’œsophage avancé/métastatique: analyse de survie de RATIONALE-306 après 3 ans de suivi

Global, randomized, phase 3 study of tislelizumab + chemotherapy versus placebo + chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): programmed death-ligand 1 (PD-L1) biomarker analysis from the RATIONALE-306 study Tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT in human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Programmed death-ligand 1 (PD-L1) biomarker analysis from RATIONALE-305 study Tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT in human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l'adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JOG/CG) avancé ou métastatique sans surexpression HER2 (HER2-négatif): Étude RATIONALE-305 – Actualisation après 36 mois de suivi Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l’adénocarcinome gastrique ou de la jonction gastro-œsophagienne (AG/JGO), avancé ou métastatique, HER2-négatif: analyse des résultats de l’étude RATIONALE-305 selon différents scores d’expression de PD-L1 Étude RATIONALE-306 comparant le Tislélizumab (TIS) + chimiothérapie (CT) versus placebo (PBO) + CT dans le carcinome épidermoïde de l’œsophage (CEO) avancé ou métastatique : analyse des résultats selon différents scores d’expression de PD-L1 Étude internationale de phase 3 évaluant tislélizumab + chimiothérapie (CT) par rapport à un placebo + CT en première ligne de traitement du carcinome épidermoïde de l’œsophage avancé/métastatique: analyse de survie de RATIONALE-306 après 3 ans de suivi

Extended follow-up of zanubrutinib-treated patients with Waldenström Macroglobulinemia from the ASPEN trial through LTE1 Sonrotoclax + zanubrutinib has high uMRD rates and good tolerability in ongoing phase 1/1b study in treatment-naive CLL Zanubrutinib + obinutuzumab vs last prior treatment in R/R follicular lymphoma: growth modulation index from ROSEWOOD Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Extended follow-up of zanubrutinib-treated patients with Waldenström Macroglobulinemia from the ASPEN trial through LTE1 Sonrotoclax + zanubrutinib has high uMRD rates and good tolerability in ongoing phase 1/1b study in treatment-naive CLL Zanubrutinib + obinutuzumab vs last prior treatment in R/R follicular lymphoma: growth modulation index from ROSEWOOD Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Alternative dosing regimens of tislelizumab proposed using modeling and simulation First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: a post hoc analysis of the RATIONALE-305 trial Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a post hoc analysis of RATIONALE-306 Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: a post hoc analysis of RATIONALE-305 study

Alternative dosing regimens of tislelizumab proposed using modeling and simulation First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: a post hoc analysis of the RATIONALE-305 trial Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first- line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a post hoc analysis of RATIONALE-306 Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: a post hoc analysis of RATIONALE-305 study.

First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors

First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors

Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstrom macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstrom macroglobulinemia CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study Evaluating reasons for differences in real-world clinical outcomes among patients with relapsed/refractory mantle cell lymphoma on covalent BTK inhibitors Impact of novel therapies on real-world clinical outcomes of patients with relapsed/refractory mantle cell lymphoma by race/ethnicity and TP53 mutation status Long-term clinical outcomes in patients with Waldenstrom macroglobulinemia who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study Long-term impact of dose interruptions of Bruton tyrosine kinase inhibitors on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400) Patient medication preferences in follicular lymphoma in the United States: a discrete choice experiment Preliminary efficacy and safety of the Bruton tyrosine kinsae degrader BGB-16673 in patients with relapsed or refractory indolent NHL: results from the phase 1 CaDAnCe-101 study Prospective patient preference study for Bruton tyrosine kinase inhibitor treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States Real-world Bruton tyrosine kinase inhibitor utilization and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: 5-year follow-up of cohort 1 from the SEQUOIA study Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies iPSC-derived CAR-γδT with novel combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study Discovery of the unique GMP-Grade iPSC clones that give rise to functional, high purity, matured CD8 αβT or γδT with exponential expansion capacity Evaluating reasons for differences in real-world (RW) clinical outcomes among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) on covalent BTK inhibitors (cBTKis) Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) by race/ethnicity and TP53 mutation status Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study Long-term impact of dose interruptions (DIs) of Bruton tyrosine kinase inhibitors (BTKis) on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia (WM) Multicenter Phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naïve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400) Patient medication preferences in follicular lymphoma (FL) in the United States (USA): a discrete choice experiment (DCE) Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (USA) Real-world Bruton tyrosine kinase inhibitor (BTKi) utilization and clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101 Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL): 5-year follow-up of cohort 1 from the SEQUOIA study Treatment with zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with another Bruton tyrosine kinase inhibitor in a US community oncology setting Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies iPSC-derived CAR-γδT with SOCS1/CISH/BIM/FAS combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies

Asia subgroup overall survival and long-term follow-up results of the phase 2b HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC) Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study

Characteristics and treatment patterns of patients diagnosed with nasopharyngeal carcinoma in Indonesia: A descriptive study using the national health insurance database Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective RATIONALE-304 long-term outcomes: First-line tislelizumab (tis) + chemotherapy (chemo) vs chemo for locally advanced or metastatic nonsquamous (NSQ) NSCLC

Asia subgroup overall survival and long-term follow-up results of the phase 2b HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC) Characteristics and treatment patterns of patients diagnosed with nasopharyngeal carcinoma in indonesia: A descriptive study using the national health insurance database Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective RATIONALE-304 long-term outcomes: First-line tislelizumab (tis) + chemotherapy (chemo) vs chemo for locally advanced or metastatic nonsquamous (NSQ) NSCLC Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study

Cost-effectiveness of zanubrutinib + obinutuzumab for treatment of relapsed or refractory follicular lymphoma in the United States Economic evaluatio of tislelizumab for the treatment of second-line esophageal squamous cell carcinoma: a lifetime partition survival model Epidemiological disparities and risk factors of esophageal cancer in Türkiye: a systematic review Examining the impact of tislelizumab added to chemotherapy on health-related quality of life (HRQoL) outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): the RATIONALE-306 study Systematic literature reivew (SLR) of randomized controlled trials (RCTs) of treatments for first-line (1L) gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) in adult patients Systematic literature review (SLR) of disease burden related to first-line (1L ) unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC) The importance of assessment design when caputuring reasons for therapeutic change in cancer care

Cost-effectiveness of zanubrutinib + obinutuzumab for treatment of relapsed or refractory follicular lymphoma in the United States Economic evaluation of tislelizumab for the treatment of second-line oesophageal squamous cell carcinoma: a lifetime partition survival model Epidemiological disparities and risk factors of esophageal cancer in Türkiye: A systematic review Examining the impact of tislelizumab added to chemotherapy on health‑related quality of life (HRQoL) outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): the RATIONALE-306 study Systematic literature review (SLR) of disease burden related to first-line (1L) unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC) Systematic literature review (SLR) of randomized controlled trials (RCTs) of treatments for first-line (1L) gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) in adult patients The importance of assessment design when capturing reasons for therapeutic change in cancer care

Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC) Global, randomized, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis (FA) results of the RATIONALE-305 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) + chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in RATIONALE-305 Tislelizumab + chemotherapy (CT) vs placebo + CT as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup

Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC) Global, randomized, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis (FA) results of the RATIONALE-305 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) + chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in RATIONALE-305 Tislelizumab + chemotherapy (CT) vs placebo + CT as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup

Zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D

Zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D

Discovery of BGB-R046, an IL-15 pro-drug that is conditionally activated by proteases in the tumor microenvironment for the treatment of cancer

Discovery of BGB-R046, an IL-15 pro-drug that is conditionally activated by proteases in the tumor microenvironment for the treatment of cancer

Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)

Combination treatment with sonrotoclax (BGB-11417) + zanubrutinib is well tolerated and achieves deep responses in patients with treatment-naive (TN) CLL/SLL: data from an ongoing phase 1/2 study Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): data from an ongoing phase 1 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable responses

Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Combination treatment with sonrotoclax (BGB-11417) + zanubrutinib is well tolerated and achieves deep responses in patients with treatment-naive (TN) CLL/SLL: data from an ongoing phase 1/2 study Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): data from an ongoing phase 1 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)

Zanubrutinib for the treatment of primary membranous nephropathy (PMN): Results of a single-arm feasibility study

Zanubrutinib for the treatment of primary membranous nephropathy (PMN): Results of a single-arm feasibility study

Safety and pharmacokinetic profile from a phase 1 trial of BGB dinutuximab beta-101 as maintenance therapy in pediatric patients with high-risk neuroblastoma in China

Safety and pharmacokinetic profile from a phase 1 trial of BGB dinutuximab beta-101 as maintenance therapy in pediatric patients with high-risk neuroblastoma in China

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia Zanubrutinib is well tolerated and effective in ibrutinib/acalabrutinib-intolerant patients with Waldenström macroglobulinemia

Improving the quality of active monitoring in Waldenström macroglobulinemia: Results of a UK-wide patient-centered experience survey and proposed standard of care for active monitoring from a UK-wide patient-expert collaboration Peripheral neuropathy in phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia Improving the quality of active monitoring in Waldenström macroglobulinemia: Results of a UK-wide patient-centered experience survey and proposed standard of care for active monitoring from a UK-wide patient-expert collaboration Peripheral neuropathy in phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: Results from the phase 1 CaDAnCe-101 study Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia

Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML) Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML) Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)

2 years of zanubrutinib in Germany: a retrospective cohort study Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM)

2 years of zanubrutinib in Germany: a retrospective cohort study Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML) Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML) Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM) Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)

Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable response

Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory (R/R) CLL/SLL show deep and durable response

First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup

First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup

Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)

Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)

A phase 2 study of sitravatinib in combination with tislelizumab versus chemotherapy in patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma that progressed on or after anti–PD-1/anti–PD-L1 antibody therapy China subgroup results of the phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma Impact of first-line treatment with tislelizumab on health-related quality of life in Chinese patients with unresectable hepatocellular carcinoma Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 1 BGB-16673-101 study

Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Updated results from a Phase Ib/II study

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: Preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): Preliminary data A phase 2 study of sitravatinib in combination with tislelizumab versus chemotherapy in patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma that progressed on or after anti–PD-1/anti–PD-L1 antibody therapy CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL China subgroup results of the phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma Efficacy and safety of tislelizumab + chemotherapy vs placebo + chemotherapy in HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 study Chinese subgroup analysis Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of first-line treatment with tislelizumab on health-related quality of life in Chinese patients with unresectable hepatocellular carcinoma Improved efficacy and safety of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in China: a subgroup of ALPINE Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Updated results from a Phase Ib/II study Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of ALPINE randomized phase 3 study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)

Combination of zanubrutinib (zanu) + venetoclax (ven) in patients with treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: Preliminary results from SEQUOIA arm D Combination treatment with sonrotoclax (sonro; BGB-11417) + zanubrutinib (zanu) is well tolerated and achieves deep responses in patients with treatment-naive CLL/SLL: Data from an ongoing phase 1/2 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses

CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab in treatment-naive CLL Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory (R/R) follicular lymphoma (FL) using the growth modulation index (GMI) Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated, with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): Data from an ongoing phase 1 study Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL): Results from the phase 1 BGB-16673-101 study Risk of hypertension in patients with CLL/SLL who participated in the ALPINE study: A post hoc analysis

CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab in treatment-naive CLL Combination of zanubrutinib (zanu) + venetoclax (ven) in patients with treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: Preliminary results from SEQUOIA arm D Combination treatment with sonrotoclax (sonro; BGB-11417) + zanubrutinib (zanu) is well tolerated and achieves deep responses in patients with treatment-naive CLL/SLL: Data from an ongoing phase 1/2 study Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory (R/R) follicular lymphoma (FL) using the growth modulation index (GMI) Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated, with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): Data from an ongoing phase 1 study Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL): Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Risk of hypertension in patients with CLL/SLL who participated in the ALPINE study: A post hoc analysis

RATIONALE-315: event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second line esophageal squamous cell carcinoma: simulated treatment comparisons Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial RATIONALE-307 long-term outcomes: first-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC Real-world overall survival (os) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in asia:a literature review Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305 Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up

Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second line esophageal squamous cell carcinoma: simulated treatment comparisons Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial RATIONALE-307 long-term outcomes: first-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC RATIONALE-315: event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC) Real-world overall survival (os) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in asia:a literature review Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305 Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up

SAFFRON-301: Tislelizumab plus sitravatinib in advanced/metastatic NSCLC progressing on/after chemotherapy and anti–PD-(L)1

SAFFRON-301: Tislelizumab plus sitravatinib in advanced/metastatic NSCLC progressing on/after chemotherapy and anti–PD-(L)1

First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life outcomes in the RATIONALE-305 study

First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life outcomes in the RATIONALE-305 study

Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting

Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting

Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305

Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305

Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis

Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL) Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive (TN) CLL Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL) Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Recent patterns of care with btk inhibitors and distribution of social determinants of health among patients with cll/sll in the us community setting Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis

A first in human phase 1a dose escalation study of BGB 15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA) Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: an open-label, single-arm, multicenter phase II study Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL) Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305

A first in human phase 1a dose escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors BGB-11417-203: an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA) Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL) Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL) Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia (CLL) patients (pts) treated with Bruton tyrosine kinase inhibitors (BTKis): a real-world data study using the Symphony Health Solutions database Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305

Budget impact analysis of zanubrutinib + obinutuzumab for the treatment of relapsed or refractory follicular lymphoma in the United States Clinical outcomes of first-line (1L) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Clinical outcomes of second-line (2L) treatments (txs) in locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a systematic literature review (SLR) Clinical outcomes of second-line and beyond (2L+) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Outcomes with novel therapies for relapsed or refractory follicular lymphoma: a targeted literature review Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients (Supplemental) Targeted literature review of cost-effectiveness models in relapsed/refractory follicular lymphoma

Budget impact analysis of zanubrutinib + obinutuzumab for the treatment of relapsed or refractory follicular lymphoma in the United States Clinical outcomes of first-line (1L) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Clinical outcomes of second-line (2L) treatments (txs) in locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a systematic literature review (SLR) Clinical outcomes of second-line and beyond (2L+) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Outcomes with novel therapies for relapsed or refractory follicular lymphoma: a targeted literature review Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients Targeted literature review of cost-effectiveness models in relapsed/refractory follicular lymphoma

Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies Ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory marginal zone lymphoma: an ongoing phase 1 study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies Ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory marginal zone lymphoma: an ongoing phase 1 study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Similar ibrutinib (ibru) efficacy across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia (R/R CLL): Matching-adjusted indirect comparison (MAIC)

Similar ibrutinib (ibru) efficacy across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia (R/R CLL): Matching-adjusted indirect comparison (MAIC)

Considerations to ensure transportability when using open claims data to conduct natural history and event rate estimation studies

Considerations to ensure transportability when using open claims data to conduct natural history and event rate estimation studies

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors AdvanTIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC) BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC

Number-needed-to-treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia

Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies

Physician-reported treatment patterns and outcomes in marginal zone lymphoma in South Korea

Physician-reported treatment patterns and outcomes in marginal zone lymphoma in South Korea Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies

Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib + obinutuzumab versus obinutuzumab monotherapy: The ROSEWOOD trial Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Similar ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: Matching-adjusted indirect comparison Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: An ongoing phase 1/2 study Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: A Q-TWiST analysis from the ALPINE study in relapsed/refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Efficacité similaire de l’ibrutinib dans les essais ALPINE et ELEVATE-RR sur la leucémie lymphoïde chronique en rechute/réfractaire : comparaison indirecte ajustée par appariement Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) First results from a phase 1, first-in-human study of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory B-cell malignancies Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib + obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Le suivi prolongé de l’étude de phase 3 randomisée ALPINE confirme que le zanubrutinib présente une supériorité à long terme sur le plan de la survie sans progression par rapport à l’ibrutinib dans le traitement de la LLC/LPL R/R Mutations acquises chez des patients atteints de leucémie lymphoïde chronique (LLC) en rechute/réfractaire ayant progressé dans l’étude ALPINE Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Premiers résultats d’une étude de phase 1 évaluant le BGB-16673, un dégradeur de la tyrosine kinase de Bruton, chez des patients atteints d’hémopathies lymphoïdes B en rechute/réfractaire Qualité de vie liée (QdV) chez les patients atteints d’un lymphome folliculaire en rechute/réfractaire (LF R/R) traités par zanubrutinib + obinutuzumab par rapport à obinutuzumab en monothérapie : l’essai ROSEWOOD Résultats à ≥ 1 an chez les patients ayant reçu zanubrutinib après un traitement par ibrutinib dans l’étude ASPEN Similar ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Sonrotoclax (BGB-11417) + zanubrutinib chez des patients présentant une leucémie lymphoide chronique / un lymphome lymphocytique (LLC/LL) non prétraités : essai de phase 1/2 en cours Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed/refractory chronic lymphocytic leukemia Toxicité, survie sans progression et qualité de vie des patients traités par zanubrutinib par rapport à ibrutinib dans la leucémie lymphoïde chronique en rechute/réfractaire : analyse Q-TWiST de l’étude ALPINE Zanubrutinib chez des patients intolérants à l’acalabrutinib atteints d’hémopathies lymphoïdes B Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Évaluation du tislélizumab, anticorps anti-PD-1, chez des patients atteints d’un lymphome de Hodgkin classique en rechute/ réfractaire : étude prospective multicentrique de phase 2 TIRHOL BGB-A317-210 du LYSA

Surgical outcomes from RATIONALE-315: Randomized, double-blind, phase 3 study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC

Surgical outcomes from RATIONALE-315: Randomized, double-blind, phase 3 study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study

Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with CLL/SLL in US community oncology practices Real-world patterns of care and financial burden among patients with follicular lymphoma in the US Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting

Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with CLL/SLL in US community oncology practices Real-world patterns of care and financial burden among patients with follicular lymphoma in the US Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting

First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup

First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian subgroup

RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

AdvanTIG-302: Anti-TIGIT monoclonal antibody ociperlimab+tislelizumab in non-small cell lung cancer

AdvanTIG-302: Anti-TIGIT monoclonal antibody ociperlimab+tislelizumab in non-small cell lung cancer

A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial

Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC) Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup

Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC) Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup

Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: data from an ongoing phase 1/2 study Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia who progressed in the ALPINE study Broad superiority of zanubrutinib over bendamustine + rituximab across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies

A phase 4, observational study evaluating the efficacy and safety of the Bruton tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with Waldenström macroglobulinemia (WM) Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Genomic landscape of ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies treated with zanubrutinib in a phase 2 study Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison

BGB-HNSCC-201 (NCT05909904): Phase 2, open-label, multi-arm, global study of tislelizumab (tis) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103

BGB-HNSCC-201 (NCT05909904): Phase 2, open-label, multi-arm, global study of tislelizumab (tis) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103

Pooled safety analysis of zanubrutinib in Asian patients with B-cell malignancies Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1l) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study Zanidatamab (ZW25; Zani) in Patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the Phase 2b HERIZON-BTC-01 study

BGB-LC-202 (NCT05577702): Phase 2 Umbrella study of tislelizumab (TIS) monotherapy and tis-based immunotherapy combina􀆟ons +/- chemotherapy (CT) as neoadjuvant treatment in chinese pa􀆟ents (pts) with resectable Stage II to IIIA non-small cell lung cancer (NSCLC) Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)

BGB-LC-202 (NCT05577702): Phase 2 Umbrella study of tislelizumab (TIS) monotherapy and tis-based immunotherapy combina􀆟ons +/- chemotherapy (CT) as neoadjuvant treatment in chinese pa􀆟ents (pts) with resectable Stage II to IIIA non-small cell lung cancer (NSCLC) Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC) Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1l) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study Zanidatamab (ZW25; Zani) in Patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the Phase 2b HERIZON-BTC-01 study

Randomized, global, Phase 3 study of tislelizumab + chemotherapy vs placebo + chemotherapy as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update

Randomized, global, Phase 3 study of tislelizumab + chemotherapy vs placebo + chemotherapy as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review

Health-related quality of life in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib vs ibrutinib in the phase 3 ASPEN trial MAHOGANY: a phase 3 trial of zanubrutinib+anti-CD20 antibodies vs lenalidomide+rituximab in relapsed/refractory follicular or marginal zone lymphoma

Health-related quality of life in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib vs ibrutinib in the phase 3 ASPEN trial MAHOGANY: a phase 3 trial of zanubrutinib+anti-CD20 antibodies vs lenalidomide+rituximab in relapsed/refractory follicular or marginal zone lymphoma

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)

A phase 2/3, multicenter, randomized, active-controlled, open-label study to evaluate the efficacy and safety of zanubrutinib in patients with primary membranous nephropathy

A phase 2/3, multicenter, randomized, active-controlled, open-label study to evaluate the efficacy and safety of zanubrutinib in patients with primary membranous nephropathy

AdvanTIG-302: Anti-TIGIT monoclonal antibody ociperlimab+tislelizumab in non-small cell lung cancer

AdvanTIG-302: Anti-TIGIT monoclonal antibody ociperlimab+tislelizumab in non-small cell lung cancer

Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study

Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain Health-related quality of life in patients (Pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (ZANU) vs ibrutinib (IBR): phase 3 ASPEN trial long-term follow-up results Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): phase 3 ASPEN trial long-term follow-up results MAHOGANY: phase III trial of zanubrutinib (Z) plus anti-CD20 antibodies against lenalidomide plus rituximab (L+R) in patients (pts.) with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) (R/R) Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) demonstrates superior progression-free survival vs ibrutinib for treatment of R/R CLL/SLL: final analysis of phase 3 ALPINE study Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib + obinutuzumab vs obinutuzumab in patients with R/R FL: updated analysis of the ROSEWOOD study

A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory follicular or marginal zone lymphoma Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: impact on health-related quality of life

Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL) A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): preliminary data Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL) Updated safety and efficacy results of zanubrutinib (zanu) in patients with B-cell malignancies who are intolerant of ibrutinib (ibr) and/or acalabrutinib (aca) Zanubrutinib (zanu) demonstrates superior progression-free survival (PFS) vs ibrutinib (ibr) for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of phase 3 ALPINE study Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study

MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma

MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab (L+R) in patients with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL)

AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity AdvanTIG-202: Phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC) AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC) Pathological response to neoadjuvant tislelizumab plus platinum-doublet chemotherapy in resectable stage II-IIIa NSCLC patients in the phase 3 RATIONALE-315 trial View Summary of Presentation in Plain Language Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: final analysis results of the RATIONALE-305 study View Summary of Presentation in Plain Language

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) Long-term follow-up of a Phase 2 Study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC) Randomized, global, Phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study

AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) AdvanTIG-202: phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC) AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC) Long-term follow-up of a phase 2 study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors Pathological response to neoadjuvant tislelizumab (tis) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC) Randomized, global, phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study

Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): RATIONALE-301 Japanese subpopulation analysis

Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): RATIONALE-301 Japanese subpopulation analysis

MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma

MAHOGANY: a phase 3 trial of zanubrutinib (zanu) plus anti-CD20 antibodies vs lenalidomide plus rituximab (L+R) in patients (pts) with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL)

Activity of zanubrutinib in Japanese patients with Waldenström macroglobulinemia Activity of zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma Efficacy and safety of zanubrutinib in Japanese patients with B-cell malignancies

Activity of zanubrutinib (zanu) in Japanese patients with Waldenström macroglobulinemia (WM) Activity of zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Efficacy and safety of zanubrutinib (zanu) in Japanese patients (pts) with B-cell malignancies

A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study

Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study

RATIONALE-305: Phase 3 study of tislelizumab (TIS) plus chemotherapy vs placebo (P) plus chemotherapy as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)

Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study

MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib

MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study

First-line chemotherapy with or without tislelizumab for extensive-stage small cell lung cancer: Rationale-312 Phase 3 study View Summary of Presentation in Plain Language

First-line chemotherapy with or without tislelizumab for extensive-stage small cell lung cancer: Rationale-312 Phase 3 study

Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a phase Ib/II study RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy versus placebo + chemotherapy as first first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma

Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a phase Ib/II study RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy versus placebo + chemotherapy as first first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population

Open insurance claims database vs closed insurance claims database to support pharmacovigilance review of potential safety events in patients with B-cell malignancies: a fit-for-purpose evaluation

Open insurance claims database vs closed insurance claims database to support pharmacovigilance review of potential safety event in patients with B-cell malignancies: a fit for purpose evaluation

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study

Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study

Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup

Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup

Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup

Evaluation of a self-administered smart phone-based application as a wellness measure in a clinical trial of zanubrutinib

Evaluation of a self-administrated smart phone-based application as a wellness measure in a clinical trial of zanubrutinib

Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the Rationale-301 study Impact of baseline liver function on overall survival and safety in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab: results from the rationale-301 study

Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the Rationale-301 study Impact of baseline liver function on overall survival and safety in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab: results from the rationale-301 study

Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study

A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL First interim analysis of a phase 1 study of zanubrutinib + lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Long-term efficacy and safety of zanubrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Matching-adjusted indirect comparison (MAIC) of zanubrutinib vs ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL) Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: post hoc analysis of a large clinical trial safety database Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life

A meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia (CLL) A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE Long-term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) vs ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life

Persistence with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib versus rituximab in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-relayed quality of life in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib vs ibrutinib: results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma in community oncology practices in the United States Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi) Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib (zanu) versus rituximab (rtx) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) Efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analysis First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (zanu) versus ibrutinib (ibru) in relapsed/refractory marginal zone lymphoma (R/R MZL) Persistence with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) The meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

Results from the pivotal phase 2b HERIZON-BTC-01 study: zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC)

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously- treated HER2-amplified biliary tract cancer (BTC) Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a Phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study

Literature review of statistical methods comparisons through simulations when using external control arm for regulatory or HTA submissions

Literature review of statistical methods comparisons through simulations when using external control arm for regulatory or HTA submissions

Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)

BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)

A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors

Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302. BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis

A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302. BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors

BGB-11417 (Bcl-2 Inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data Zanubrutinib demonstrates superior progression-free survival versus ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis

A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial

A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin's lymphoma or Waldenström macroglobulinemia ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214) trial Zanubrutinib demonstrates superior progression-free survival versus ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis

Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma Real-world treatment patterns and economic burden of patients with marginal zone lymphoma Zanubrutinib demonstrates superior progression-free survival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib Zanubrutinib demonstrates superior progression-free survival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

Prediction of drug-drug interactions with a moderate CYP3A inducer: development and validation of a physiologically based pharmacokinetic model of rifabutin

Prediction of drug-drug interactions (DDI) with a moderate CYP3A inducer: development and validation of physiologically-based pharmacokinetic (PBPK) model of rifabutin

RATIONALE-301 : analyse finale de l’étude randomisée de phase 3 comparant le tislélizumab au sorafénib en première ligne de traitement du carcinome hépatocellulaire non résécable

RATIONALE-301 : analyse finale de l’étude randomisée de phase 3 comparant le tislélizumab au sorafénib en première ligne de traitement du carcinome hépatocellulaire non résécable

Impact of tislelizumab on health-related quality of life in asian patients with esophageal squamous cell carcinoma

Impact of tislelizumab on health-related quality of life in asian patients with esophageal squamous cell carcinoma

Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib Zanubrutinib in patients with B-cell malignancies intolerant to acalabrutinib

Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study Rate of cardiac disorders in patients (pts) with B-cell malignancies who undergo treatment with zanubrutinib (zanu) Zanubrutinib (zanu) in patients (pts) with B-cell malignancies intolerant to acalabrutinib (acala)

Liver metastases are associated with a unique tumor microenvironment and impaired treatment outcomes in urothelial bladder cancer patients treated with tislelizumab

Liver metastases are associated with a unique tumor microenvironment and impaired treatment outcomes in urothelial bladder cancer patients treated with tislelizumab

Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial

Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial

RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population

Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population

RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Zanubrutinib demonstrates superior progression-free surivival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relaped/refractory MCL: an updated pooled analysis Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a nonrandomized, open-label, phase 1b/2 study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML) Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like? Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced NSCLC AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer: RATIONALE-304 updated analysis Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer: RATIONALE-307 updated analysis

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced non-small cell lung cancer AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer : RATIONALE-304 updated analysis Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer : RATIONALE-307 updated analysis

Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC) Randomized, global, phase 3 study of tislelizumab plus chemotherapy vs chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): Asia subgroup Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: the RATIONALE-301 Chinese subpopulation analysis

Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma

Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset RATIONALE-302: tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): impact on health-related quality of life (HRQoL) in Asian patients RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC) Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 Chinese subpopulation analysis

Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (Bcl-2) inhibitor, in patients with acute myeloid leukemia

Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer

DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study

DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data Long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)

Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States Budget impact analysis of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States

Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States Budget impact of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia in the United States Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study

RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for nonsquamous nsclc in patients aged 65-75 years HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (her2+) advanced/metastatic gastroesophageal adenocarcinoma HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303

Time to response and depth of response in non-squamous non-small cell lung cancer patients treated with tislelizumab plus chemotherapy as first line therapy: an exploratory analysis of RATIONALE-304 Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first line treatment for nonsquamous non-small cell lung cancer in patients aged 65-75 years Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma A matching-adjusted indirect comparison of tislelizumab versus camrelizumab as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) AdvanTIG-105: a phase 1 dose-verification study of ociperlimab in combination with tislelizumab in advanced solid tumors in Chinese patients AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML) Rationale-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study Tislelizumab versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer: sub-analysis from phase 3 RATIONALE-303 randomized clinical study Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303 Zanubrutinib plus obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial

Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103 Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103

Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer

ASPEN biomarker analysis: response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia harboring CXCR4, TP53, and TERT mutations ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Extended follow-up of a phase 2 trial of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia Zanubrutinib in patients intolerant to ibrutinib/acalabrutinib Zanubrutinib or the treatment of patients with Waldenström macroglobulinemia: 4 years of follow-up

Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia

ASPEN biomarker analysis: response to Bruton Tyrosine Kinase Inhibitor (BTKi) treatment in patients with Waldenström macroglobulinemia (WM) harboring CXCR4, TP53, and TERT mutations ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM) Extended follow-up of a phase 2 trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia Preliminary results for patients with Waldenström macroglobulinemia from the phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQOL)

Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib

Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib

Interim safety analysis of zanubrutinib in Japanese patients with mature B-cell malignancies

Interim safety analysis of zanubrutinib in Japanese patients with mature B-cell malignancies

A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)

Randomized, phase 3 study of second-line treatment vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life

A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC) Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQOL)

A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM) First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (Bcl-2) inhibitor, in patients with acute myeloid leukemia (AML) SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve CLL/SLL

Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review

A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM) First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML) SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)

A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs. ibrutinib in patients with Waldenström macroglobulinemia First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma: subgroup analysis of the MAGNOLIA study Zanubrutinib plus obtinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial

A phase 2 study with the novel B-cell lymphoma (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia

A phase 2 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients (pts) with B-cell malignancies: preliminary data ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Zanubrutinib (zanu) in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC

AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC